Patients with juvenile idiopathic arthritis, particularly those with oligoarticular JIA, receive biologic DMARD therapy sooner on public insurance compared to private insurance. A study conducted at Cincinnati Children’s Hospital Medical Center found that publicly insured patients started biologic DMARDs earlier but took longer to achieve clinically inactive disease compared to those with private insurance. This study highlights the impact of insurance type on treatment initiation and outcomes for JIA patients. Further research is needed to explore other factors such as adherence to treatment, distance to medical center, and social deprivation indexes that may influence disease response in these patients.
Source link
Public insurance leads to faster bDMARD initiation in juvenile idiopathic arthritis
